Top Page
Mach7 Technologies
(Sydney:M7T)
Mach7 Technologies (M7T) vs. iShares MSCI Australia ETF (EWA)
Mach7 Technologies Business Overview & Revenue Model
Mach7 Technologies Earnings Call Summary
Mach7 Technologies Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.79M | 33.79M | 17.24M | 30.06M | 27.08M | 19.03M |
| Gross Profit | 8.38M | 8.38M | -6.42M | 9.35M | -2.57M | -7.73M |
| EBITDA | -7.06M | -7.06M | -15.09M | 2.09M | 2.80M | -1.83M |
| Net Income | -6.20M | -6.20M | -7.97M | -1.05M | -4.17M | -9.36M |
Balance Sheet | ||||||
| Total Assets | 64.21M | 64.21M | 73.03M | 82.31M | 78.92M | 76.97M |
| Cash, Cash Equivalents and Short-Term Investments | 23.07M | 23.07M | 26.18M | 23.39M | 25.75M | 18.36M |
| Total Debt | 1.12M | 1.12M | 1.27M | 1.20M | 1.33M | 1.08M |
| Total Liabilities | 18.63M | 18.63M | 21.17M | 22.82M | 20.55M | 19.05M |
| Stockholders Equity | 45.58M | 45.58M | 51.86M | 59.48M | 58.38M | 57.91M |
Cash Flow | ||||||
| Free Cash Flow | 112.92K | 112.92K | 3.30M | -2.97M | 5.94M | 1.40M |
| Operating Cash Flow | 868.59K | 868.59K | 3.45M | -2.61M | 6.37M | 1.50M |
| Investing Cash Flow | -1.70M | -1.70M | -391.31K | -361.01K | -438.56K | -42.33M |
| Financing Cash Flow | -2.43M | -2.43M | -32.08K | -68.63K | 547.61K | 11.21M |
Mach7 Technologies Technical Analysis
Mach7 Technologies Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$126.24M | 78.33 | 1.89% | ― | 10.06% | ― | |
55 Neutral | $75.19M | ― | -12.35% | ― | 15.99% | 22.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$23.25M | -12.89 | -17.05% | ― | 28.91% | -1050.00% | |
48 Neutral | AU$58.12M | -9.39 | -13.83% | ― | 3.61% | -17.03% | |
41 Neutral | AU$16.45M | -0.24 | -240.60% | ― | -48.41% | -7200.00% | |
40 Underperform | AU$84.39M | -11.89 | ― | ― | ― | ― |
Mach7 Technologies Corporate Events
Mach7 Technologies Limited announced a change in the interests of its director, Robert Bazzani, who has acquired an additional 100,000 fully paid ordinary shares through on-market purchases. This acquisition increases Bazzani’s total holding to 354,728 shares, reflecting a strategic move that may signal confidence in the company’s growth prospects and potentially impact stakeholder perceptions positively.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.81 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies reported a significant quarter with key developments including the initial deployment of its solutions in the U.S. Veterans Health Administration’s National Teleradiology Program. This quarter marked a strategic reset with leadership changes and a focus on high-value enterprise opportunities in Asia and the Middle East. The company achieved a CARR of A$29.6M and an ARR run rate of A$23.5M, highlighting its financial stability with no debt and cash reserves of A$18.9M. The company is poised for growth with a streamlined leadership team and expanded operations in Malaysia, aiming for sustained momentum and a rebound in the latter half of FY26.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies has announced the successful execution of Phase 1 of its collaboration with the Veterans Health Administration’s National Teleradiology Program, providing its Vendor Neutral Archive and eUnity Diagnostic Viewer. This phase, which has a potential contract value of A$11.7 million, marks a significant milestone for Mach7, highlighting its strengths in interoperability and cloud computing. The successful rollout could lead to further expansion into the VHA hospital network, enhancing diagnostic capabilities for veterans across 125 sites.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies Limited has announced its Annual General Meeting (AGM) will be held virtually on November 28, 2025, at 10:00 am AEDT. The meeting will be conducted via a Zoom webinar, allowing shareholders to participate in real-time by listening to proceedings, viewing presentations, asking questions, and voting. The company encourages shareholders to lodge their proxies by November 26, 2025, and provides options for accessing meeting-related documents electronically or physically. This virtual AGM reflects the company’s commitment to engaging with its stakeholders while leveraging technology to facilitate participation.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting their commitment to transparency and accountability. This announcement reinforces Mach7’s dedication to maintaining robust governance practices, which is crucial for its stakeholders and enhances its reputation in the healthcare technology sector.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies’ Annual Report for FY25 highlights its strategic direction, product innovation, and customer impact. The report emphasizes the company’s commitment to transparency, strategic execution, and improving clinical outcomes through its enterprise imaging platform. Key priorities include enhancing clinical impact, delivering customer value, and advancing product development. The company aims to drive sustainable growth through strategic partnerships and operational excellence, reflecting its dedication to long-term value creation for stakeholders.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies announced the release of its Q1 FY26 results on 31 October 2025, followed by a webinar hosted by CEO Teri Thomas and CFO Dan Lee. This event provides an opportunity for investors to engage with the company’s leadership, reflecting Mach7’s commitment to transparency and stakeholder communication.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies Limited announced the cessation of certain securities, specifically 723,000 performance rights and 718,334 options, due to the expiry and lapse of conditions, respectively. This announcement may impact the company’s capital structure and could influence investor perceptions, as it reflects changes in the company’s financial instruments and potential adjustments in strategic planning.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.81 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies has announced the date for its 2025 Annual General Meeting, scheduled for November 28, 2025, in Melbourne. This meeting will be crucial for stakeholders as it includes the closing date for director nominations, which is set for October 10, 2025, potentially impacting the company’s leadership and strategic direction.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.81 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies Limited has announced the issuance of 350,000 unquoted equity securities under an employee incentive scheme. This strategic move aims to motivate and retain key personnel, potentially strengthening the company’s operational capabilities and market position in the healthcare technology sector.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.81 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies has announced the appointment of Daniel Lee as their new Chief Financial Officer, effective September 25, 2025. With nearly 20 years of experience in driving growth and profitability in various sectors, including SaaS and healthcare technology, Lee is expected to play a crucial role in supporting Mach7’s strategic transformation and growth ambitions, enhancing shareholder value.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.81 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies Ltd., an Australian company, specializes in developing medical imaging software solutions for healthcare organizations worldwide, offering products like the eUnity Enterprise Diagnostic Viewer and Vendor Neutral Archive. In its latest earnings report for the fiscal year ending June 2025, Mach7 Technologies reported a 16% increase in revenue to AUD 33.8 million, while reducing its net loss by 22% to AUD 6.2 million compared to the previous year. The company’s sales orders totaled AUD 29.1 million, with a significant portion coming from annual recurring revenue, reflecting a shift towards subscription-based sales. Despite a challenging market, Mach7 maintained a strong gross margin of 94% and achieved positive operating cash flow, ending the year with AUD 23.1 million in cash reserves. Looking ahead, Mach7 Technologies aims to capitalize on its innovative product offerings and customer-centric strategies to drive growth, particularly focusing on expanding its market share in North America, Asia Pacific, and the Middle East.
Mach7 Technologies reported a strong financial performance for FY25, with a 16% increase in total revenue to A$33.8M, driven by a 20% rise in recurring revenue. The company achieved a positive operating cash flow and improved its EBITDA significantly, reflecting strong revenue growth and cost control. With A$23.1M in cash and no debt, Mach7 is well-positioned for future growth. The company plans to focus on refining its customer model and expanding its global footprint to enhance customer support and R&D capabilities, particularly in North America.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies Limited has released its preliminary final report and audited financial statements for the year ending June 30, 2025. This announcement provides stakeholders with insights into the company’s financial performance and operational progress over the past year, which is crucial for evaluating its market position and future prospects.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies announced the resignation of its Chief Financial Officer, Dyan O’Herne, effective September 30, 2025. Ms. O’Herne, who has been with the company for nine years and served as CFO since January 2023, contributed significantly to strengthening Mach7’s financial and operational framework. The company has initiated a search for a new CFO and will provide updates upon appointment.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.95 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.